Onco-hematology
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma
27 Jan, 2023 | 11:58h | UTCCommentaries:
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's 🆕 Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients
24 Jan, 2023 | 14:28h | UTC
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma
13 Jan, 2023 | 13:12h | UTCCommentaries:
Commentary from the author on Twitter (thread – click for more)
👉With the dust from #ASH22 settled, we are happy to highlight the inaugural output from the #HoLISTIC consortium: The Advanced-stage cHL International Prognostication Index (A-HIPI) presented at @ASH_hematology w/ simult pub in @ASCO @JCO (https://t.co/em6HENzngk). A thread 1/16 pic.twitter.com/2kicNMBEIj
— Andrew M. Evens, DO, MBA, MSc (@DrAEvens) December 31, 2022
An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants
13 Jan, 2023 | 13:10h | UTC
Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma
12 Jan, 2023 | 12:56h | UTCInvited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology
Special Issue | American Society of Hematology Education Program (series of open-access review articles)
10 Jan, 2023 | 14:26h | UTCHomepage: American Society of Hematology Education Program – Hematology
RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.
16 Dec, 2022 | 13:33h | UTCZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post
Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.
12 Dec, 2022 | 12:38h | UTCTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA
— NEJM (@NEJM) December 10, 2022
Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.
12 Dec, 2022 | 12:37h | UTCGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4
— NEJM (@NEJM) December 11, 2022
Review | AL Amyloidosis for Cardiologists.
6 Dec, 2022 | 13:36h | UTC
Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.
30 Nov, 2022 | 13:39h | UTC
Consensus Paper | Hematopoietic cell transplantation in the management of myelodysplastic syndrome.
29 Nov, 2022 | 14:11h | UTC
Post-trial follow-up | OS with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma.
25 Nov, 2022 | 12:25h | UTCOriginal Study: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
RCT | Zanubrutinib vs. Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
22 Nov, 2022 | 13:03h | UTC
M-A | Prophylactic platelet transfusions vs. no prophylaxis in hospitalized patients with thrombocytopenia.
21 Nov, 2022 | 13:59h | UTC
Single-arm P1/2 study | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma.
11 Nov, 2022 | 13:05h | UTCIberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentaries on Twitter
In a phase I trial of the novel cereblon E3 ligase modulator iberdomide+dexamethasone in pts with RRMM, SAEs occurred in 53%, with one treatment-related death. The ORRs were 32% in the dose-escalation (n=90) & 26% in the dose-expansion (n=107) cohorts: https://t.co/rfRCUfCABb
— NatureRevClinOncol (@NatRevClinOncol) October 14, 2022
NEW research: iberdomide plus dexa was generally safe and showed meaningful clinical activity in heavily pretreated patients with multiple myeloma, including in disease that was refractory to immunomodulatory drugs in this ph 1-2 trial #mmsmhttps://t.co/x1ta31eKtk pic.twitter.com/2URVIoFIAi
— The Lancet Haematology (@TheLancetHaem) October 7, 2022
RCT | Prophylactic tranexamic acid did not decrease bleeding in patients with hematologic malignancy.
10 Nov, 2022 | 13:36h | UTCCommentary: Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies – Physician’s Weekly
RCT | Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin’s Lymphoma.
4 Nov, 2022 | 13:30h | UTCBrentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort Study | Prognostic value of FLT3-internal tandem duplication residual disease in AML.
3 Nov, 2022 | 13:36h | UTC
Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
31 Oct, 2022 | 13:36h | UTC
Commentary on Twitter
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/hw7Tp9yjdu pic.twitter.com/CqMu2cMqRc
— Blood Journal (@BloodJournal) August 31, 2022
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition